Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Yabao Pharmaceutical Group Co Days Payable?
Yabao Pharmaceutical Group CoSHSE:600351 -3.53%70 Days Payable is 43.69 as of Mar. 2026, which is 26% below its 10-year median of 59.22. GuruFocus rates SHSE:600351 with a GF Score™ of 70/100 and a GF Value™ of ¥5.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks worse than 77.35% on this metric.
The historical rank and industry rank for Yabao Pharmaceutical Group Co's Days Payable or its related term are showing as below:
SHSE:600351'
s Days Payable Range Over the Past 10 Years
Min: 47.4 Med: 59.22 Max: 73.82
Current: 47.4
During the past 13 years, Yabao Pharmaceutical Group Co's highest Days Payable was 73.82. The lowest was 47.40. And the median was 59.22.
SHSE:600351's Days Payable is ranked worse than 77.35% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SHSE:600351: 47.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yabao Pharmaceutical Group Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Yabao Pharmaceutical Group Co's Days Payable falls into.
Yabao Pharmaceutical Group Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yabao Pharmaceutical Group Co (SHSE:600351) has a Days Payable of 43.69 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Yabao Pharmaceutical Group Co and its competitors. This is 26% below median its historical median of 59.22. Over the past decade, Yabao Pharmaceutical Group Co's Days Payable has ranged from 47.40 to 73.82. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #717 out of 927 companies in the Drug Manufacturers industry, placing it in the top 77.3%.
Is Yabao Pharmaceutical Group Co's Days Payable too high?
Yabao Pharmaceutical Group Co's current Days Payable of 43.69 is 26% below median its 10-year median of 59.22. Over the past 10 years, this metric has ranged from a low of 47.40 to a high of 73.82. The Drug Manufacturers industry median Days Payable is 90.38. Yabao Pharmaceutical Group Co's value of 43.69 is 51.7% below this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #717 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #717 out of 927 companies for Days Payable. This places Yabao Pharmaceutical Group Co in the lower half of its industry. The industry median Days Payable is 90.38. Yabao Pharmaceutical Group Co's value of 43.69 is 51.7% below this benchmark. Historically, Yabao Pharmaceutical Group Co's own Days Payable has ranged from 47.40 to 73.82 over the past decade. While the company's 10-year median is 59.22 vs. the industry median of 90.38, Yabao Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current Days Payable of 43.69 is 51.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Yabao Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current Days Payable is 43.69, which is 26% below median its own 10-year median of 59.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.53, compared to a current price of ¥6.56 — trading 18.6% above its estimated fair value. The current Days Payable is 43.69, which is 26% below median its 10-year median of 59.22 and 51.7% below the Drug Manufacturers industry median of 90.38. Yabao Pharmaceutical Group Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Days Payable is 43.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥6.56 is trading 18.6% above its estimated GF Value™ of ¥5.53.
GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:600351:
Days Payable: 43.69 (26% below median its 10-year median of 59.22)
GF Value™: ¥5.53 vs. price of ¥6.56 (18.6% above fair value)
Industry Position: 51.7% below the Drug Manufacturers median (#717 of 927)
No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yabao Pharmaceutical Group Co Business Description
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
70GF Score
Get the complete analysis for SHSE:600351
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600351 has been successfully added to your 
